The pooled estimates may be underestimates of the efficacy of newer agents, although the review could not determine whether stronger weight-loss effects necessarily translate into greater reductions in binge eating
Nh dng thm kem chng nng nh
It is an exceptional pathway for individuals sensitive to standard medication side effects, patients managing autoimmune conditions like Hashimotos or PCOS, or those looking to maintain prior weight loss long-term
10.4103/0019-5545.44908 [DOI] [PMC free article] [PubMed] [Google Scholar] Ochiai T., Sano T., Nagayama T., Kubota N., Kadowaki T., Wakabayashi T., et al
Future direction The evolution of GLP-1RAs is increasingly shifting toward oral formulations, aiming to enhance patient adherence by eliminating the need for injections and addressing the logistical complexities associated with traditional peptide therapies [72, 73]
More than half of patients (53%) stop using GLP-1s within the first year, according to a December 2025 Sermo survey of physicians
